Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Keytruda | Pembrolizumab | For locally advanced or metastatic urothelial carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Besponsa | Inotuzumab Ozogamicin | Acute Lymphoblastic Leukemia (ALL) | Reimburse with clinical criteria and/or conditions | Complete | ||
Prevymis | letermovir | Cytomegalovirus infection, prophylaxis | Reimburse with clinical criteria and/or conditions | Complete | ||
Siliq | brodalumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
Vosevi | sofosbuvir velpatasvir voxilaprevir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
Adcetris | Brentuximab Vedotin | HL at high risk of relapse or progression post-ASCT | Reimburse with clinical criteria and/or conditions | Complete | ||
Alecensaro | Alectinib | Anaplastic Lymphoma Kinase-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Bavencio | Avelumab | metastatic Merkel Cell Carcinoma (mMCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Stivarga | Regorafenib | Unresectable Hepatocellular Carcinoma (HCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Kisqali | Ribociclib | Advanced or Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete |